At the same time, as our understanding of the biology of hematologic malignancies has continued to expand, compounds targeting proteins or signaling pathways disrupted by recurrently mutated genes have become available, notably inhibitors to EZH2 in follicular lymphoma and FLT3, IDH1, and IDH2 in AML60,61. Here, IDH2 is linked to follicular lymphoma.